BCL2 and B-cell chronic lymphocytic leukemia: Moreover, with the novel agent venetoclax, which inhibits anti-apoptotic BCL2, leading to the apoptosis of CLL cells and is used in different clinical settings from first-line to relapse settings [24,25,26,27], physicians now have a broad spectrum of treatment options.